Health Economics

Phagenesis, a medical device company specializing in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and Sectoral Asset Management

Retrieved on: 
Monday, March 4, 2024

The combined European and United States investment syndicate was led by EQT Life Sciences, and co-led by Sectoral, with new investors British Patient Capital, Northern Gritstone and Aphelion/Cardeation Capital also joining the round.

Key Points: 
  • The combined European and United States investment syndicate was led by EQT Life Sciences, and co-led by Sectoral, with new investors British Patient Capital, Northern Gritstone and Aphelion/Cardeation Capital also joining the round.
  • Patients with swallowing dysfunction (dysphagia) are unable to safely or effectively eat, drink, or manage their own saliva.
  • Dysphagia can often lead to life threatening complications such as pneumonia and is also associated with substantially higher healthcare costs.
  • Drew Burdon, Partner at EQT Life Sciences, said: "Dysphagia is a severe medical condition that affects countless patients in hospital.

Phagenesis, a medical device company specializing in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and Sectoral Asset Management

Retrieved on: 
Monday, March 4, 2024

The combined European and United States investment syndicate was led by EQT Life Sciences, and co-led by Sectoral, with new investors British Patient Capital, Northern Gritstone and Aphelion/Cardeation Capital also joining the round.

Key Points: 
  • The combined European and United States investment syndicate was led by EQT Life Sciences, and co-led by Sectoral, with new investors British Patient Capital, Northern Gritstone and Aphelion/Cardeation Capital also joining the round.
  • Patients with swallowing dysfunction (dysphagia) are unable to safely or effectively eat, drink, or manage their own saliva.
  • Dysphagia can often lead to life threatening complications such as pneumonia and is also associated with substantially higher healthcare costs.
  • Drew Burdon, Partner at EQT Life Sciences, said: "Dysphagia is a severe medical condition that affects countless patients in hospital.

Poor, middle-aged Australians are more likely to die from cancer – and the gap is widening

Retrieved on: 
Wednesday, August 9, 2023

But our fresh analysis shows what happens next can depend on how much money you have and where you live.

Key Points: 
  • But our fresh analysis shows what happens next can depend on how much money you have and where you live.
  • Among middle-aged Australians cancer is the leading cause of death, accounting for 45% of all deaths among those aged 45 to 64 years.
  • In an article just published in Health Economics, we examine the inequality in mortality (or death rates) across Australia.

Measuring death and status

    • We used death registry data provided by the Australian Institute of Health and Wellbeing and Census data on SES.
    • The new findings for middle-aged Australians stand out because inequality in mortality has been relatively stable over time and death rates are falling for most other age groups.
    • Among young Australians aged 15–24 years we can see death rates falling and the SES gap in mortality shrinking due to greater declines in road deaths in poor areas.

Why the gap?

    • Our research suggests different access to health care may have a role to play.
    • This suggests the widening gap is because of smaller declines in deaths over time in our poorest regional and remote areas.
    • Second, over the period from 2001 to 2018, the number of doctors per person is consistently greater in richer regions than poorer regions of Australia.
    • However, access to new medications and treatments is often only available following consultations with primary physicians (such as GPs) or specialists.

More analysis needed

    • But we need more comprehensive analysis of how various social determinants of health contribute to these inequalities.
    • These could include social and environmental characteristics of local areas, health behaviours and cancer awareness, income or income inequality.
    • Future research should examine whether the socioeconomic disparities in cancer death rates are also evident in cancer diagnoses.

'All United for MG' organises first-ever European Myasthenia Gravis Day on June 2nd leads to pan-European call for action supported by European leaders

Retrieved on: 
Thursday, June 1, 2023

BRUSSELS, June 1, 2023 /PRNewswire/ -- The #AllUnitedforMG coalition, with the institutional support of argenx, brings together European patient associations and representatives from Belgium, France, Germany, Greece, Italy, Romania, Poland and Spain and aims to create awareness and gain recognition of this life-threatening disease, strengthen patients' rights for a better quality of life and obtain better patient care. The disease affects between 56.000 and 100.000 people in Europe 4.

Key Points: 
  • "Raising awareness about myasthenia gravis is not just about spreading knowledge, it's about empowering those who are living with it.
  • Our aim is to enhance patients' quality of life and reduce their mental burden," conclude the founders of the European Myasthenia Gravis Day.
  • "The first European Awareness Day for Myasthenia Gravis marks an important milestone towards increasing awareness and understanding of this rare disease.
  • Therefore we are very happy that there is finally a European Myasthenia Gravis Day to put a spotlight on this disease."

'All United for MG' organises first-ever European Myasthenia Gravis Day on June 2nd leads to pan-European call for action supported by European leaders

Retrieved on: 
Thursday, June 1, 2023

BRUSSELS, June 1, 2023 /PRNewswire/ -- The #AllUnitedforMG coalition, with the institutional support of argenx, brings together European patient associations and representatives from Belgium, France, Germany, Greece, Italy, Romania, Poland and Spain and aims to create awareness and gain recognition of this life-threatening disease, strengthen patients' rights for a better quality of life and obtain better patient care. The disease affects between 56.000 and 100.000 people in Europe 4.

Key Points: 
  • "Raising awareness about myasthenia gravis is not just about spreading knowledge, it's about empowering those who are living with it.
  • Our aim is to enhance patients' quality of life and reduce their mental burden," conclude the founders of the European Myasthenia Gravis Day.
  • "The first European Awareness Day for Myasthenia Gravis marks an important milestone towards increasing awareness and understanding of this rare disease.
  • Therefore we are very happy that there is finally a European Myasthenia Gravis Day to put a spotlight on this disease."

Inspira Technologies Appoints Dr. Nir as Chief Medical Officer

Retrieved on: 
Tuesday, May 30, 2023

RA'ANANA, Israel, May 30, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, has announced the appointment of Dr. Adi Rizansky Nir, PhD to the position of Chief Medical Officer ("CMO"). Dr. Nir brings a wealth of expertise and a distinguished track record in the field of medicine and healthcare administration to the Company.

Key Points: 
  • Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, has announced the appointment of Dr. Adi Rizansky Nir, PhD to the position of Chief Medical Officer ("CMO").
  • As CMO, Dr. Nir will play a critical role in overseeing and guiding Inspira's medical operations and strategic initiatives.
  • On the appointment, Inspira Technologies' CEO, Dagi Ben Noon said, "We are thrilled to have Dr. Nir as our new CMO.
  • Please join us in welcoming Dr. Nir to her new position in our Inspira Technologies family.

The Pharma Mini MBA Training Course: Featuring Business School Pharmaceutical Case Studies

Retrieved on: 
Friday, April 21, 2023

BSc (Economics), MSc (Health Economics) Leela Barham is an independent health economist and policy expert working on a freelance basis.

Key Points: 
  • BSc (Economics), MSc (Health Economics) Leela Barham is an independent health economist and policy expert working on a freelance basis.
  • This follows 7 years at a specialist economic consulting firm working in a small dedicated health and pharmaceutical team.
  • She regularly writes on hot topics affecting the industry for Pharmaceutical Executive, Pharmaphorum and EyeforPharma and has also written for PharmaTimes, and Pharma Pricing and Reimbursement.
  • Dr Laura Brown MBA, BSc,PhD, is a Pharmaceutical QA and Training Consultant, Course Director for the MSc in Clinical Research, School of Pharmacy at the University of Cardiff.

The Pharma Mini MBA Training Course: Accelerated Management Programme for Pharmaceutical Industry Employees - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 19, 2023

BSc (Economics), MSc (Health Economics) Leela Barham is an independent health economist and policy expert working on a freelance basis.

Key Points: 
  • BSc (Economics), MSc (Health Economics) Leela Barham is an independent health economist and policy expert working on a freelance basis.
  • This follows 7 years at a specialist economic consulting firm working in a small dedicated health and pharmaceutical team.
  • She regularly writes on hot topics affecting the industry for Pharmaceutical Executive, Pharmaphorum and EyeforPharma and has also written for PharmaTimes, and Pharma Pricing and Reimbursement.
  • She has a particular expertise in quality assurance including risked based approaches to quality systems, data Integrity and project management in the pharmaceutical industry.

MDIC Publishes White Paper on Using Patient Preference Information for Coverage Decision Making

Retrieved on: 
Tuesday, December 6, 2022

The Health Economics and Patient Value (HEPV) initiative at the Medical Device Innovation Consortium (MDIC) has released the white paper, How Can Patient Preference Information Be Used in Payer Coverage Decisions and Health Technology Assessment?

Key Points: 
  • The Health Economics and Patient Value (HEPV) initiative at the Medical Device Innovation Consortium (MDIC) has released the white paper, How Can Patient Preference Information Be Used in Payer Coverage Decisions and Health Technology Assessment?
  • In the development of this technical paper, MDIC set out to understand how to incorporate patient preference information (PPI) in coverage decision making by payers and health technology assessment (HTA) organizations.
  • It is the first MDIC resource focused specifically on awareness of patient preference and methods as a tool for payers and the medical device industry.
  • This MDIC initiative seeks to encourage the use of patient preference information by clarifying the standards and role of generating this data and presenting it in a more consistent, systematic format.

Audere Announces the Appointment of Dr. Doris Macharia to Board of Directors

Retrieved on: 
Wednesday, November 30, 2022

Audere , a digital health nonprofit developing solutions to advance health equity, today announced the appointment of Dr. Doris Macharia to its Board of Directors.

Key Points: 
  • Audere , a digital health nonprofit developing solutions to advance health equity, today announced the appointment of Dr. Doris Macharia to its Board of Directors.
  • Dr. Macharia is the Senior Vice President of Global Programs at Orbis International and brings extensive international global health expertise to Audere.
  • View the full release here: https://www.businesswire.com/news/home/20221130005184/en/
    Dr. Doris Macharia has more than twenty five years of experience in global health and development, spanning managerial, operational, and technical roles throughout the industry.
  • Dr. Macharias unique perspective will enrich our leadership, and I am proud to welcome her to our Board of Directors!